Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $16.10 Analyst target: $26.25 Upside: 63.04%
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. The company is headquartered in Novato, California.
See the full interactive analysis & chart →Informational only — not investment advice.